BioPorto (BIOPOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioPorto (BIOPOR) has a cash flow conversion efficiency ratio of -0.575x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-20.23 Million ≈ $-3.16 Million USD) by net assets (Dkr35.18 Million ≈ $5.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioPorto - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how BioPorto's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BioPorto debt and liabilities for a breakdown of total debt and financial obligations.
BioPorto Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioPorto ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Media Prima Bhd
KLSE:4502
|
0.055x |
|
Wanbury Limited
NSE:WANBURY
|
-0.053x |
|
Bridgemarq Real Estate Services Inc
TO:BRE
|
-0.014x |
|
Prozone Realty Limited
NSE:PROZONER
|
0.044x |
|
ALT5 Sigma Corporation
NASDAQ:ALTS
|
-0.006x |
|
New Delhi Television Limited
NSE:NDTV
|
1.199x |
|
Panda Financial Holding Corp Ltd
SHG:600599
|
0.459x |
|
Afluente Transmissão de Energia Elétrica S.A
SA:AFLT3
|
0.067x |
Annual Cash Flow Conversion Efficiency for BioPorto (2000–2024)
The table below shows the annual cash flow conversion efficiency of BioPorto from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of BioPorto.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Dkr67.78 Million ≈ $10.60 Million |
Dkr-83.58 Million ≈ $-13.08 Million |
-1.233x | -33.78% |
| 2023-12-31 | Dkr60.16 Million ≈ $9.41 Million |
Dkr-55.46 Million ≈ $-8.68 Million |
-0.922x | -23.33% |
| 2022-12-31 | Dkr70.22 Million ≈ $10.99 Million |
Dkr-52.48 Million ≈ $-8.21 Million |
-0.747x | +46.80% |
| 2021-12-31 | Dkr45.96 Million ≈ $7.19 Million |
Dkr-64.58 Million ≈ $-10.10 Million |
-1.405x | -298.07% |
| 2020-12-31 | Dkr100.91 Million ≈ $15.79 Million |
Dkr-35.62 Million ≈ $-5.57 Million |
-0.353x | +85.15% |
| 2019-12-31 | Dkr25.32 Million ≈ $3.96 Million |
Dkr-60.16 Million ≈ $-9.41 Million |
-2.376x | -251.29% |
| 2018-12-31 | Dkr56.20 Million ≈ $8.79 Million |
Dkr-38.01 Million ≈ $-5.95 Million |
-0.676x | -28.99% |
| 2017-12-31 | Dkr56.07 Million ≈ $8.77 Million |
Dkr-29.40 Million ≈ $-4.60 Million |
-0.524x | -18.13% |
| 2016-12-31 | Dkr44.29 Million ≈ $6.93 Million |
Dkr-19.66 Million ≈ $-3.08 Million |
-0.444x | -19.14% |
| 2015-12-31 | Dkr44.48 Million ≈ $6.96 Million |
Dkr-16.57 Million ≈ $-2.59 Million |
-0.373x | +33.77% |
| 2014-12-31 | Dkr28.69 Million ≈ $4.49 Million |
Dkr-16.14 Million ≈ $-2.52 Million |
-0.563x | -44.91% |
| 2013-12-31 | Dkr42.86 Million ≈ $6.71 Million |
Dkr-16.64 Million ≈ $-2.60 Million |
-0.388x | -102.92% |
| 2012-12-31 | Dkr-1.15 Million ≈ $-179.93K |
Dkr-15.28 Million ≈ $-2.39 Million |
13.287x | +484.76% |
| 2011-12-31 | Dkr3.94 Million ≈ $616.44K |
Dkr-13.61 Million ≈ $-2.13 Million |
-3.453x | +14.59% |
| 2010-12-31 | Dkr3.31 Million ≈ $517.72K |
Dkr-13.38 Million ≈ $-2.09 Million |
-4.043x | -368.99% |
| 2009-12-31 | Dkr15.41 Million ≈ $2.41 Million |
Dkr-13.29 Million ≈ $-2.08 Million |
-0.862x | +2.57% |
| 2008-12-31 | Dkr15.50 Million ≈ $2.43 Million |
Dkr-13.72 Million ≈ $-2.15 Million |
-0.885x | -84.47% |
| 2007-12-31 | Dkr29.45 Million ≈ $4.61 Million |
Dkr-14.13 Million ≈ $-2.21 Million |
-0.480x | -62897.70% |
| 2006-12-31 | Dkr-17.62 Million ≈ $-2.76 Million |
Dkr-13.46K ≈ $-2.11K |
0.001x | -83.18% |
| 2005-12-31 | Dkr-3.06 Million ≈ $-478.13K |
Dkr-13.88K ≈ $-2.17K |
0.005x | -99.19% |
| 2000-12-31 | Dkr894.00K ≈ $139.87K |
Dkr503.00K ≈ $78.70K |
0.563x | -- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neu… Read more